DRUG STUDY

Generic Brand Classification Mechanism Nursing Consideration Contraindication Dosage/Frequency Route

Name Name of Action

Ampicilin Polycillin Antibiotics Interferes • Monitor appropriate Hypersensitivity to Maximum • ORAL

Penicillin with bacterial laboratory tests as ordered. ampicillin, other recommended
cell wall penicillins, or dosage, 8-14 g/day Onset: 30 min
synthesis •Monitor for (teach patient cyclosporines. (reserve 14 g of
during active to monitor and report) serious infections, Peak: 2 hr
multiplication, effectiveness of therapy such as meningitis,
causing cell and adverse reactions as septicemia) may be Duration: 6-8 hr
wall death and identified above, including given IV, IM, or
resultant development of PO. Use parenteral • IM:
bactericidal opportunistic infections. routes for severe
activity infections; switch to Onset: 30 min
against oral route as soon as
susceptible possible. Peak: 2 hr
bacteria.
Duration: 6-8hr

• IV:

Onset: Immediate

Peak: 5min

Duration: 6-8hr

23
 DRUG STUDY

Generic Name Brand Classificatio Mechanism Nursing Contraindication Dosage/Frequency Route

Name n of Action Consideration

.
Vancomycin Lyphocin, Unclassified Inhibits • Monitor for signs Hypersensitivity to • Adults: • ORAL
Hydrochloride Vancocin; Antimicrobial bacterial or symptoms of vancomycin or any Capsule: 125 mg,
Vancoled s, Anti- cell wall adverse reactions component; patint 250 mg Onset: Varies
infective synthesis. indicated above, with previous severe Powder for oral
Agent. especially auditory hearing loss. solution: 1g, 10g Peak: 2-4 hr
and renal function. Powder for
injection: 500mg,
• Monitor for 1g, 2g, 5g, 10g
maculppapular rash
appearance on the
face, neck, trunk,
and upper
extremities.

24
 DRUG STUDY

Generic Brand Classification Mechanism Nursing Contraindication Dosage/Frequency Route

Name Name of Action Consideration

• Assess for previous Hypersensitivity • Adults • ORAL

Ceftriaxone Rocephin Cephalosporin Inhibits history of reactions to to ceftriaxone 1-2 g/day IM or IV Onset: Rapid
, Anti- bacterial other cephalosporins or sodium, any once a day or in
infective cell wall penicillins. component, or equal divided doses Peak: Immediate
agents; synthesis by • Monitor for allergic other bid. Do not exceed
Bacteriacidal binding to reactions.These can cephalosporins. 4 g/day. Duration: 15-18 hr
one or more occur a few days after
of the therapy is initiated. • Pediatric Patients: •IM:
penicillin- • Assess for potential 50-75 mg/kg/day
binding nephrotoxicity. IV or IM in divided Onset: 30 min
proteins. doses every 12 hr.
Do not exceed Peak: 1.5-4 hr
2g/day.
Duration:
15-18 hr

25
 DRUG STUDY

Generic Brand Classification Mechanism Nursing Contraindicatio Dosage/Frequency Route

Name Name of Action Consideration n

Dexamethaso Decadron Adrenocortico Decreases •Monitor for Opthalmic: Use • Adult: • ORAL
ne Dalalone steroids; Anti- inflammation effectiveness of in viral, fungal, Dexamethasone sodium Onset: Slow
inflammatory by therapy. or tuberculosis phosphate: Peak: 1-2 hr
Agents suppressionof • Follow prescribe disease of the Aerosol: Duration: 2-3 days
migrationof rim\nstruction for eye Oral: 84mcg
polymorphon administration.• Systemic or dexamethasone per • IM:
uclear Monitor systemic Topical: Active activation (12.6g)
leukolytes and adverse effects untreated Onset: Rapid
reversal of closely. infections. • Topical: Cream: 0.1% Peak: 30-60 min
increased with methylcellulose Duration: 2-3
capillary 0.5% (5mL, 15mL) days
permealbillity
; suppresses • IV:
normal
immune Onset: Rapid
response Peak: 30-60 min
Duration: 2-3
days

26
 DRUG STUDY

Generic Name Brand Classification Mechanism Nursing Contraindicatio Dosage/Frequency Route

Name of Action Consideratio n
n

Rifampin Rifadin Antitubercular, Inhibits •Monitor for Hypersensitivity • Adult: • ORAL

Anti-infective bacterial RNA effectiveness to rifampin or Capsule: 150 mg, 300 Onset: Varies
Agents; synthesis by of therapy. any component mg Peak: 1-4 hr
Antibiotic: binding to the • Follow Powder for injection:
Antituberculotic beta subunit prescribe 600 mg (contains a • IV:
( first line) of DNA- rim\nstruction sulfite)
dependent for Onset: Rapid
RNA administration
polymerase, .• Monitor Peak: End of
blocking RNA systemic infusion
transcription adverse
effects
closely.

27